title: Management of Hypereosinophilic Syndromes.
abstract: The symptomatic hypereosinophilic patient must be approached in a stepwise manner, with thorough assessment to determine whether the hypereosinophilia itself is contributing to damage and disease manifestations (thereby defining a hypereosinophilic syndrome), and to identify an eventual cause of hypereosinophilia, followed by initiation of treatment directed against the underlying condition or deleterious hypereosinophilic state. Situations encountered in the clinic are extremely heterogeneous because of the numerous potential causes of hypereosinophilia and the variable spectrum of eosinophil-mediated organ damage. A practical approach to many of these situations is presented in this review.
authors.affiliation: Department of Internal Medicine, Hôpital Erasme, Institute for Medical Immunology, Université Libre de Bruxelles, 808 Route de Lennik, Brussels 1070, Belgium. Electronic address: florence.roufosse@erasme.ulb.ac.be.
authors.forename: Florence
authors.initials: F
authors.lastname: Roufosse
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D004804:Eosinophils / Q000166:cytology / Q000473:pathology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007938:Leukemia; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors*; D039221:mRNA Cleavage and Polyadenylation Factors / Q000037:antagonists & inhibitors*
chemical_list: D000305:Adrenal Cortex Hormones; C479818:FIP1L1 protein, human; D016898:Interferon-alpha; D047428:Protein Kinase Inhibitors; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; D020796:Receptor, Platelet-Derived Growth Factor alpha; D006918:Hydroxyurea
keywords: Corticosteroid; FIP1L1-PDGFRA–associated myeloid neoplasm; Hydroxyurea; Idiopathic hypereosinophilic syndrome; Imatinib mesylate; Interferon-α; Lymphocytic variant hypereosinophilic syndrome; Targeted therapy